Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

SIMPLE SUMMARY: Carfilzomib with dexamethasone is an important therapeutic option for patients with relapsed/refractory multiple myeloma. We sought to evaluate the effect of this regimen on the bone-related outcomes, which are associated with both quality of life and survival. Among 25 patients, les...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Katodritou, Eirini, Kyrtsonis, Marie-Christine, Douka, Vassiliki, Spanoudakis, Emmanouil, Papatheodorou, Athanasios, Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Gavriatopoulou, Maria, Makras, Polyzois, Kastritis, Efstathios, Dimopoulos, Meletios A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998249/
https://www.ncbi.nlm.nih.gov/pubmed/33809268
http://dx.doi.org/10.3390/cancers13061257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998249/
https://www.ncbi.nlm.nih.gov/pubmed/33809268
http://dx.doi.org/10.3390/cancers13061257

Ejemplares similares